首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL17C |
| Uniprot No | Q9P0M4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-197aa |
| 氨基酸序列 | HH DPSLRGHPHS HGTPHCYSAE ELPLGQAPPH LLARGAKWGQ ALPVALVSSL EAASHRGRHE RPSATTQCPV LRPEEVLEAD THQRSISPWR YRVDTDEDRY PQKLAFAECL CRGCIDARTG RETAALNSVR LLQSLLVLRR RPCSRDGSGL PTPGAFAFHT EFIHVPVGCT CVLPRSV |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-17C重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*IL-17C regulates the innate immune function of epithelial cells in an autocrine manner*
**作者**：Reynolds JM et al.
**摘要**：研究发现IL-17C通过结合受体IL-17RE/IL-17RA复合体，在皮肤和肠道上皮细胞中自分泌激活，促进抗菌肽和炎症因子表达，增强屏障防御并加剧炎症反应。
2. **文献名称**：*IL-17C is required for lethal inflammation during airway fungal infection*
**作者**：Ramirez-Carrozzi V et al.
**摘要**：在小鼠真菌性肺炎模型中，IL-17C由上皮细胞分泌，通过招募中性粒细胞和激活Th17免疫应答，导致过度炎症反应，重组IL-17C蛋白加剧肺组织损伤。
3. **文献名称**：*Targeting IL-17C in colorectal cancer inhibits tumor growth and induces immune protection*
**作者**：Song X et al.
**摘要**：IL-17C在结直肠癌中高表达，重组IL-17C蛋白体外实验显示其促进癌细胞迁移;动物模型中抑制IL-17C信号可减少肿瘤进展并增强抗肿瘤T细胞活性。
IL17C is a member of the interleukin-17 (IL-17) cytokine family, which comprises six members (IL-17A to IL-17F) involved in regulating immune responses, particularly at barrier surfaces. Discovered in 2000. IL17C shares structural homology with other IL-17 family proteins, featuring a conserved cysteine-knot fold. Unlike IL17A and IL17F—primarily produced by T cells—IL17C is predominantly expressed by epithelial cells and keratinocytes in response to pathogen-associated molecular patterns (PAMPs) or tissue damage signals. It plays a critical role in mucosal immunity, skin inflammation, and host defense by promoting the production of pro-inflammatory cytokines, antimicrobial peptides, and chemokines.
Recombinant IL17C refers to the engineered protein produced in vitro using expression systems like mammalian cells or bacteria. This protein retains the biological activity of native IL17C, enabling functional studies. Researchers utilize recombinant IL17C to investigate its signaling mechanisms, particularly its interaction with the IL17RA/IL17RE receptor complex, which activates NF-κB and MAPK pathways. Such studies highlight its dual role: protective in acute infections (e.g., fungal or bacterial) but pathogenic in chronic inflammatory diseases like psoriasis, colitis, or asthma.
Therapeutic interest in IL17C has grown due to its tissue-specific actions. Inhibitors targeting IL17C or its receptors are explored for treating autoimmune and inflammatory disorders, while recombinant IL17C itself may aid in modeling diseases or augmenting epithelial immunity. However, its functional overlap with other IL-17 family members and context-dependent effects necessitate careful evaluation. Current research focuses on delineating its precise contributions to immunity and pathology, aiming to harness its potential without exacerbating inflammatory cascades.
×
